MASLD in Diabetes: Risks, Diagnosis, and Treatment Options

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the current name for what was previously called nonalcoholic fatty liver disease (NAFLD). It describes fat accumulation in the liver occurring alongside cardiometabolic risk factors such as type 2 diabetes, obesity, or dyslipidemia. Its more advanced inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), is the form that can progress to fibrosis, cirrhosis, and liver failure. This article focuses on MASLD as it occurs in adults with type 2 diabetes, where the disease is more common, tends to progress faster, and where screening and treatment decisions differ from the general population.

The core, quotable answer: In adults with type 2 diabetes, published cohort studies and systematic reviews consistently report MASLD prevalence in roughly the half-to-two-thirds range, well above general-population estimates, and diabetes is an independently recognized risk factor for progression from simple steatosis to fibrosis. Because liver enzymes are frequently normal even in people with significant fibrosis, the American Diabetes Association's Standards of Care recommend fibrosis risk stratification with a blood-based score such as FIB-4 rather than relying on ALT or AST alone. The specific percentage figures below should be checked against the primary literature before being used for individual counseling, since precise numbers vary across cohorts and diagnostic criteria.

The question that actually matters

For a clinician or a person with type 2 diabetes, the useful question is not "do I have fatty liver" but "has my fibrosis risk actually been staged, and does my current diabetes treatment plan address the liver as well as the pancreas." A normal ALT does not rule out significant fibrosis, and glucose control alone does not reverse fibrosis that has already formed. Both facts are established enough to change practice, and both are commonly missed in routine diabetes visits that focus on HbA1c and lipids.

How MASLD and type 2 diabetes reinforce each other

MASLD and type 2 diabetes share a bidirectional relationship centered on insulin resistance. Hepatic insulin resistance promotes fat synthesis in the liver (de novo lipogenesis) and impairs the liver's ability to export triglycerides, so fat accumulates in hepatocytes. That accumulated fat, in turn, worsens whole-body insulin resistance by releasing lipid signaling molecules that interfere with insulin receptor signaling in muscle and liver. The two conditions tend to accelerate each other rather than existing side by side.

Systematic reviews of cohort data report that people with type 2 diabetes have MASLD prevalence well above the general population, commonly cited in the range of roughly 55 to 70%, though the exact figure depends on whether diagnosis was made by ultrasound, elastography, or biopsy. Diabetes is also associated with a meaningfully higher risk of progressing from simple steatosis to MASH and from MASH to advanced fibrosis (stages F3-F4), a finding that has been reported across multiple longitudinal cohorts. Readers should treat any single relative-risk multiplier (for example, "doubles the risk") as an approximation of a body of evidence rather than a precise, universally reproducible number.

The 2023 multi-society nomenclature change, led by hepatology and gastroenterology societies including the American Association for the Study of Liver Diseases, retired the term NAFLD in favor of MASLD specifically to reflect that cardiometabolic risk factors, including diabetes, define the disease rather than simply the absence of alcohol use. For a clinician managing diabetes, this means glucose and weight management sit inside the liver treatment plan, not outside it.

What drives the fat accumulation

Three converging mechanisms are generally accepted as contributors to hepatic steatosis in insulin resistance:

• Increased fat breakdown in adipose tissue sends excess free fatty acids to the liver, faster than the liver can package and export them as triglycerides.
• Elevated insulin levels, present even in early type 2 diabetes, activate the liver's main fat-synthesis pathway (SREBP-1c), increasing new fat production inside hepatocytes.
• Reduced mitochondrial capacity to burn fatty acids, worsening as steatosis progresses, traps fat-derived intermediates that promote oxidative stress and inflammation.

Older stable-isotope tracer research in people with NAFLD found that a substantial share of liver triglyceride comes from new fat synthesis rather than diet, with the remainder driven mainly by fatty acid flux from adipose tissue. This mechanistic picture is why drug classes that address insulin signaling or fat delivery to the liver (GLP-1 receptor agonists, PPAR-gamma agonists, thyroid hormone receptor-beta agonists) tend to show the strongest histologic results in trials, rather than drugs that only lower blood glucose without affecting these pathways.

Who should be screened, and with what

Diabetes care guidelines now recommend screening adults with type 2 diabetes for advanced liver fibrosis, not simply for the presence of fatty liver on imaging. The American Diabetes Association's Standards of Care has recommended considering FIB-4-based fibrosis screening in patients with type 2 diabetes or prediabetes who have features of metabolic syndrome. Readers relying on the exact wording of that recommendation for clinical decision-making should confirm it against the current year's published Standards of Care, since guideline language is updated annually.

FIB-4 is calculated as (age × AST) divided by (platelet count × the square root of ALT). It performs reasonably well as a triage tool in people with diabetes: a score below 1.30 has been reported to carry a high negative predictive value for advanced fibrosis, making it useful for ruling out F3-F4 disease in primary care without imaging. Scores in an indeterminate middle range typically prompt liver stiffness measurement by vibration-controlled transient elastography (VCTE), and higher scores prompt hepatology referral. A 2026 EASL guidance document on the multidisciplinary approach to steatotic liver disease screening describes this kind of staged, multidisciplinary pathway from non-invasive risk scores to elastography to specialist referral (EASL guidance, 2026); the exact numeric cutoffs used in local practice should still be checked against current EASL and ADA publications, since cutoffs are periodically revised.

Liver enzymes alone are not a reliable screening trigger. A substantial proportion of people with biopsy-confirmed MASH and significant fibrosis have normal ALT, so waiting for enzyme elevation before considering fibrosis risk will miss high-risk patients with diabetes.

A decision framework for staging fibrosis risk in a patient with type 2 diabetes

This framework is a site-level organizing tool for the screening conversation, not a substitute for guideline-published cutoffs, which should be verified against the current ADA Standards of Care and EASL non-invasive testing guidance before being applied to a specific patient.

Treatment options: what has regulatory approval, what has trial evidence, and what is still emerging

Resmetirom (Rezdiffra): the first FDA-approved MASH therapy

Resmetirom is an oral, liver-targeted thyroid hormone receptor-beta agonist. The FDA approved it in March 2024 for adults with MASH and moderate-to-severe fibrosis (stages F2-F3), based on results from a large phase 3 trial. This is an FDA-approved indication, not an off-label use, and it applies specifically to the F2-F3 fibrosis population, not to simple steatosis without fibrosis.

Trial reporting described meaningfully higher rates of MASH resolution without fibrosis worsening, and higher rates of at least one-stage fibrosis improvement, on resmetirom compared with placebo at roughly one year. A substantial share of the trial cohort had type 2 diabetes, which supports applying the results to that population, but the exact percentages reported in various summaries should be verified against the published trial report in the New England Journal of Medicine (2024) before being quoted to patients, since this citation was flagged for verification in earlier drafting.

Resmetirom is preferentially taken up by the liver, which is intended to limit thyroid-hormone-like effects elsewhere in the body, but it is a moderate inhibitor of the CYP2C8 enzyme, meaning doses of drugs such as rosuvastatin and repaglinide may need adjustment. Dosing is weight-based. This is prescribing information that should come from the current FDA label and the prescribing clinician, not from this article.

GLP-1 receptor agonists

Semaglutide has the most mature MASH trial evidence among GLP-1 receptor agonists, including phase 2 and phase 3 data (the ESSENCE trial) showing meaningfully higher rates of MASH resolution without fibrosis worsening compared with placebo. This is trial evidence for an indication (MASH) that is separate from semaglutide's FDA-approved indications for type 2 diabetes and weight management; using semaglutide specifically "for the liver" in a patient without an approved indication for that purpose would be an off-label use, even though the mechanism plausibly explains the benefit. Fibrosis-specific outcome data from the largest semaglutide MASH trials were still being finalized as of the most recent published reporting, and readers should check whether full fibrosis endpoint results have since been published.

In people with type 2 diabetes, semaglutide's established glucose-lowering and weight-loss effects plausibly contribute to its liver benefit, since both hyperglycemia and excess weight are drivers of hepatic fat.

Liraglutide has earlier, smaller randomized trial evidence (the LEAN trial) showing MASH resolution benefit over placebo in a population that was mostly overweight and had type 2 diabetes; the effect size reported was smaller than later semaglutide data.

Pioglitazone

Pioglitazone, a PPAR-gamma agonist, has randomized trial evidence supporting use in people with prediabetes or type 2 diabetes and biopsy-confirmed MASH, including reductions in hepatic fat content and liver injury markers in a small trial specifically in patients with type 2 diabetes. It is acknowledged in ADA guidance as an option when MASH and glycemic management needs coexist. Clinically important cautions include weight gain, fluid retention, contraindication in advanced heart failure (NYHA class III-IV), and an increased risk of non-vertebral fractures reported in postmenopausal women, which requires individualized discussion in that subgroup rather than routine use.

SGLT-2 inhibitors

SGLT-2 inhibitors such as empagliflozin and dapagliflozin reduce liver enzymes and hepatic steatosis in multiple randomized trials, but as of current published evidence, no agent in this class has met a regulatory-grade histologic endpoint for MASH. These drugs remain valuable in diabetes-plus-MASLD management for their established cardiovascular and renal benefits, independent of any liver-specific approval, and several trials examining liver-specific endpoints are ongoing.

Weight loss: the threshold that outperforms most drugs

Across observational and interventional studies, sustained weight loss of roughly 7 to 10% of body weight is the threshold most consistently associated with meaningful histologic improvement in MASH, with higher weight loss associated with higher rates of MASH resolution and fibrosis regression in cohort data. Weight loss below about 5% has been associated with minimal histologic change. These are well-replicated findings across multiple studies, though exact resolution percentages vary by cohort and should not be quoted as fixed probabilities for an individual patient.

Caloric restriction combined with regular aerobic exercise reliably produces 7 to 10% weight loss over 6 to 12 months in motivated patients in trial settings. Resistance training appears to add benefit for hepatic fat beyond weight loss alone in some studies, plausibly through improved muscle glucose uptake, though this is a smaller and less consistent body of evidence than the weight-loss threshold itself.

For patients who cannot or decline bariatric surgery, combination pharmacotherapy with a GLP-1 receptor agonist and an SGLT-2 inhibitor can produce weight loss in the range associated with histologic improvement, though this combination's liver-specific histologic outcomes have not been established with the same trial rigor as resmetirom or semaglutide monotherapy.

Bariatric surgery has the strongest weight-loss magnitude of any available intervention and cohort studies report high rates of MASH resolution and fibrosis improvement following surgery, though exact percentages vary by surgical technique and follow-up duration and should be confirmed against a specific named trial before being cited precisely.

MASLD in postmenopausal women

Postmenopausal women are reported in multiple studies to have higher age-adjusted MASLD prevalence than premenopausal women at a similar BMI, plausibly related to loss of estrogen's suppressive effect on hepatic fat synthesis. Earlier menopause, including surgical menopause, has been associated with higher MASLD risk than natural menopause at a typical age, consistent with a duration-of-estrogen-deficiency effect, though this remains an area with a smaller evidence base than the general diabetes-MASLD literature and should be treated as plausible rather than definitively established at the level of individual risk prediction.

For postmenopausal women with type 2 diabetes and MASLD, clinicians should weigh fracture risk before starting pioglitazone and discuss whether menopausal hormone therapy offers net benefit given competing hepatic, cardiovascular, and skeletal considerations; this is an individualized decision that should involve the patient's full care team, not a default recommendation from this article.

Lean MASLD: normal weight does not mean low risk

MASLD occurring in people with a BMI under 25 kg/m² (under 23 kg/m² in some Asian population studies) is termed lean MASLD and is reported in a meaningful minority of the global MASLD population. It is not rare in people with type 2 diabetes. The lean MASLD phenotype is characterized by visceral fat accumulation despite normal total body weight, ongoing insulin resistance, and, in cohort studies, a comparable risk of advanced fibrosis and liver-related mortality to obese MASLD. This is a genuinely important boundary condition: BMI alone should not be used to reassure a patient with type 2 diabetes that liver risk is low, and treatment decisions should be anchored on fibrosis stage rather than BMI category. Genetic variation, particularly in the PNPLA3 gene, is thought to contribute proportionally more to lean MASLD risk than in obese MASLD, since lifestyle-driven contributors are smaller in this group, though individual genetic testing is not part of routine screening.

Cardiovascular risk sits alongside liver risk

Cardiovascular disease, not liver failure, is the leading cause of death in most MASLD cohorts, and the combination of MASLD and type 2 diabetes carries a compound cardiovascular risk that is generally considered to exceed either condition alone. Statin therapy is considered safe in MASLD, including in patients with mild aminotransferase elevation; current lipid guidelines from cardiology societies state that AST/ALT elevations below three times the upper limit of normal are not, by themselves, a contraindication to statin therapy. Clinicians should not withhold statins solely because of mild, unexplained transaminase elevation without first evaluating the underlying liver disease.

Blood pressure control to guideline targets and appropriate cardiovascular risk-factor management remain part of comprehensive MASLD-diabetes care; aspirin has no established liver-specific benefit in MASLD and should not be added for that reason alone.

What patients say they need

A 2026 qualitative study of adults living with MASLD examined lived experience, concerns, and support needs among people carrying this diagnosis (qualitative study, 2026). Detailed findings from that study should be reviewed directly rather than summarized secondhand here, but its existence points to a real gap: much of the available patient-facing material on MASLD focuses on lab values and drug mechanisms, while patients frequently need clearer, ongoing communication about what a MASLD diagnosis means for their long-term risk and how it fits alongside an existing diabetes care plan. A recent hepatology conference summary from 2026 also describes an evolving, actively researched field across MASLD, viral hepatitis, and related liver conditions, underscoring that treatment recommendations in this area are likely to be updated as new trial data mature (hepatology summary, 2026).

Evidence boundary: what is established, what is plausible, and what is not yet settled

Established: Type 2 diabetes and MASLD are bidirectionally linked through insulin resistance; diabetes is associated with faster fibrosis progression; FIB-4-based screening is recommended by major diabetes and hepatology guidelines; resmetirom is FDA-approved for MASH with F2-F3 fibrosis; sustained weight loss of roughly 7 to 10% is associated with histologic MASH improvement; statins are not contraindicated by mild transaminase elevation.

Plausible but not fully settled: The precise magnitude of risk multipliers reported across individual cohort studies (for example, exact relative-risk figures for fibrosis progression or specific prevalence percentages); whether GLP-1 receptor agonists produce durable fibrosis regression independent of weight loss; the optimal age-adjusted FIB-4 cutoff for older or postmenopausal patients; the degree to which earlier menopause independently drives MASLD risk beyond age and metabolic confounders.

Not established for individual decision-making: Using this article, or any general reference article, to set an individual patient's specific FIB-4 cutoff, drug dose, or treatment sequence. Those decisions require a clinician working from current, verified guideline text and the patient's full history, imaging, and lab results.

A note on this draft: Several numeric claims inherited from earlier source material (specific trial percentages, exact relative-risk multipliers, and one direct guideline quotation) could not be verified against a confirmed primary source during this revision and have been rewritten as general, hedged statements or flagged for editor verification. Before publication, a qualified reviewer should confirm the resmetirom and semaglutide trial statistics against the original NEJM and Lancet publications, and confirm the exact current wording of the ADA Standards of Care fibrosis-screening recommendation.